American Oriental Bioengineering, Inc. Stock

Equities

AOBI

US0287315032

Pharmaceuticals

Market Closed - OTC Markets 08:10:00 2023-12-11 pm EST 5-day change 1st Jan Change
0.0005 USD -.--% Intraday chart for American Oriental Bioengineering, Inc. -.--% -.--%
Sales 2011 213M Sales 2012 145M Capitalization 13.35M
Net income 2011 -67M Net income 2012 -59M EV / Sales 2011 0.5 x
Net Debt 2011 63.31M Net Debt 2012 49.49M EV / Sales 2012 0.43 x
P/E ratio 2011
-0.62 x
P/E ratio 2012
-0.22 x
Employees 3,719
Yield 2011 *
-
Yield 2012
-
Free-Float 5.48%
More Fundamentals * Assessed data
Dynamic Chart
1 year
0.00
Extreme 0.0005
0.00
3 years
0.00
Extreme 0.0002
6.75
5 years
0.00
Extreme 0.0002
6.75
10 years
0.00
Extreme 0.0002
6.75
More quotes
Managers TitleAgeSince
Founder 55 -
Chief Executive Officer 71 70-11-29
Members of the board TitleAgeSince
Chief Executive Officer 71 70-11-29
Founder 55 -
More insiders
American Oriental Bioengineering, Inc. is an integrated pharmaceutical company. The Company is engaged in development, manufacture and commercialization of a broad range of pharmaceutical and healthcare products. The Company’s business consists of prescription pharmaceutical products, over-the-counter pharmaceutical products and nutraceutical products. Two flagship prescription pharmaceutical products marketed in China are Shuanghuanglian Lyophilized Injection Powder, or SHL Injection Powder, and Cease Enuresis Soft Gel, or CE Gel. Over-the-counter pharmaceutical products are similar to its prescription pharmaceutical products in that they need approval from the SFDA. Its products in this category include Jinji Series, Cease Enuresis Patch (CE Patch), and Boke Series. Nutraceutical products are intended for the overall well-being. It markets several nutraceutical products in China, which include its soybean peptide based drinks, tablets, powder and instant coffee.
More about the company